MedTrace Logo

Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia

NCT04275414 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2020-09-14

No results posted yet for this study

Summary

The novel identified coronavirus (SARS-CoV-2) in 2019 causes an nationwide outbreak as well as public health crisis in China, and expands globally. Pulmonary edema is one of the most detrimental symptoms and usually presents in severe and critical coronavirus disease (COVID-19), resulting in dyspnea, acute lung injury (ALI) ,acute respiratory distress syndrome (ARDS), and even death. Recent evidence revealed higher levels of blood Vascular Endothelial Growth Factor (VEGF) in COVID-19 patients compared with healthy controls. VEGF is considered as the most potent vascular permeability inducers. Numerous studies have revealed that VEGF was a key factor and a potential therapeutic target in ALI and ARDS. Bevacizumab, an anti-VEGF drug, approved by the FDA on February 26, 2004 and widely used in clinical oncotherapy, is a promising drug for ALI/ARDS in COVID-19 through suppression of pulmonary edema.

Conditions

  • Coronavirus Infections

Interventions

DRUG

Bevacizumab Injection

Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min

Sponsors & Collaborators

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • Moriggia-Pelascini Gravedona Hospital

    collaborator UNKNOWN

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Yuguo Chen, Dr · Qilu Hospital of Shandong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-15
Primary Completion
2020-04-05
Completion
2020-05-02

Countries

  • China
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04275414 on ClinicalTrials.gov